
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : GRT-001
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Forbion
Deal Size : $100.0 million
Deal Type : Series B Financing
Granite Bio Debuts with $100 Million of Capital
Details : The financing aims to fund the development of Granite pipeline including GRT-001, it depletes pro-inflammatory monocytes, key drivers of autoimmunity and inflammation. It is being evaluated for IBD.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
April 24, 2025
Lead Product(s) : GRT-001
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Forbion
Deal Size : $100.0 million
Deal Type : Series B Financing

Contact Us!